| Year |
Citation |
Score |
| 2016 |
Yamamoto Y, Yamaoka H, Tanaka M, Okazaki H, Ozaki T, Takano Y, Lin JF, Fujita H, Kagayama T, Shimizu K, Hiraoka N, Ishii H, Liao YF, Tsuei KD, Mizuki J. Origin of Pressure-induced Superconducting Phase in KxFe2-ySe2 studied by Synchrotron X-ray Diffraction and Spectroscopy. Scientific Reports. 6: 30946. PMID 27499373 DOI: 10.1038/Srep30946 |
0.312 |
|
| 2016 |
Tsuburaya R, Takahashi J, Nakamura A, Nozaki E, Sugi M, Yamamoto Y, Hiramoto T, Horiguchi S, Inoue K, Goto T, Kato A, Shinozaki T, Ishida E, Miyata S, Yasuda S, et al. Beneficial effects of long-acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation: The NOVEL study. European Heart Journal. PMID 27354043 DOI: 10.1093/eurheartj/ehw256 |
0.313 |
|
| 2016 |
Okazaki H, Shirakabe A, Kobayashi N, Hata N, Shinada T, Matsushita M, Yamamoto Y, Shibuya J, Shiomura R, Nishigoori S, Asai K, Shimizu W. The prognostic impact of uric acid in patients with severely decompensated acute heart failure. Journal of Cardiology. PMID 27261247 DOI: 10.1016/j.jjcc.2016.04.013 |
0.326 |
|
| 2012 |
Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, Tanabe K, Morino Y, Akasaka T, Takatsu Y, Nishikawa H, Yamamoto Y, Nakagawa Y, Hayashi Y, Iwabuchi M, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). Circulation. 126: 1225-36. PMID 22824435 DOI: 10.1161/CIRCULATIONAHA.112.104059 |
0.375 |
|
| Show low-probability matches. |